6JH0 Stock Chart & Stats
€1.15
--
Market closed
€1.15
--
Day’s Range― - ―
52-Week Range€0.98 - €2.12
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€11.50M
Enterprise Value-€12.77M
Total Cash (Recent Filing)€21.94M
Total Debt (Recent Filing)€2.35M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.39Price Target Upside281.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Glioblastoma (GBM)Demonstrated ~97% improvement in median PFS versus standard of care in GBM is a meaningful, durable clinical signal in a high-unmet-need indication. Such persuasive efficacy and a clean safety profile can materially de-risk the program, support regulatory engagement, attract partners, and increase long-term value if replicated in confirmatory studies.
Low Leverage With Declining DebtVery low debt and declining absolute borrowings provide a conservatively levered balance sheet, reducing bankruptcy and interest-rate risks. This structural strength preserves strategic optionality, making it easier to prioritize R&D and partnership deals over servicing debt, improving long-term operational resilience.
Improving Cash Burn And Strengthened Cash BalanceA strengthened cash position (~$21.9M) combined with materially reduced burn versus prior years extends runway to reach late-2026 clinical and regulatory milestones. Sustained burn improvement supports continued R&D investment and reduces immediate financing pressure, improving the odds of achieving value-driving de-risking events.
Bears Say
No Commercial RevenueAs a clinical-stage biotech with no product sales, IN8bio lacks recurring commercial cash inflows. This structural absence of revenue means long-term operations depend on successful clinical progress, partnerships, or financing; until commercialization, the business model remains funding-dependent and higher risk.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow (~-$14.5M TTM) indicates the company cannot self-fund development. Even with improved burn, continued negative cash generation forces recurring capital raises or partner financing, constraining strategic autonomy and increasing dilution or leverage risk over the medium term.
Dependence On Equity Financing (ATM Program)The adoption of a new at-the-market equity program and termination of the prior facility highlight ongoing reliance on equity markets for cash. This structural financing approach creates dilution risk, ties execution to market access, and can limit long-term shareholder alignment if capital needs persist around development timelines.
IN8bio News
6JH0 FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was €0.97 and its highest was €2.12 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is €11.50M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on May 07, 2026. The company reported -€0.228 earnings per share for the quarter, beating the consensus estimate of -€0.543 by €0.314.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.3.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,847,089 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -€0.228 in its last earnings report, beating expectations of -€0.543. Following the earnings report the stock price went down -0.827%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in DE:6JH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
6JH0 Stock 12 Month Forecast
Average Price Target
€4.39
▲(281.50% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―
Options Prices
Currently, No data available
---